Navigation Links
Transition Therapeutics Announces Dates for Upcoming Corporate Events
Date:12/1/2008

TORONTO, Dec. 1 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH, NASDAQ: TTHI) today announced the dates for the following upcoming corporate events:

20th Annual Piper Jaffray Health Care Conference

Transition will present at the upcoming 20th Annual Piper Jaffray Health Care Conference. The presentation will take place on Tuesday, December 2nd, 2008 at 12:30 P.M. (Eastern Time) at the New York Palace.

2008 Annual General Meeting of Shareholders

Transition's Annual General Meeting will occur Monday, December 8, 2008 at the MaRS Centre, South Tower, 101 College Street, Main Floor, Room CR-3, Toronto, Ontario at 4:00 P.M. (Eastern Time).

2008 Healthcare Conference hosted by RBC Capital Markets

Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition, will participate in the upcoming 2008 Healthcare Conference hosted by RBC Capital Markets. Dr. Cruz is scheduled to participate in a panel session titled "The Challenge of Alzheimer's Disease" on Thursday, December 11th, 2008 between 12:30 - 1:25 P.M. (Eastern Time) at the Westin Times Square New York. A live webcast and archived version of this event will be available on the Transition website www.transitiontherapeutics.com.

    About Transition
    ----------------

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
2. Respiratory Leaders Urge Medical Community to Educate Patients Transitioning CFC to HFA Inhalers
3. Transitions Optical to Provide Free Vision Screenings at the American Diabetes Associations Feria de Salud por tu Familia(TM)
4. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
5. Schering-Plough Announces Transition of Animal Health Leadership
6. ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program
7. MidSouth eHealth Alliance to Transition to Commercial Software Solution from Informatics Corporation of America
8. Transition Therapeutics Announces No Material Change
9. Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans
10. Transition Therapeutics Announces Executive Management Appointments
11. AGA Medical Announces Management Transition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: